Scientists have demonstrated how some fast-growing bacteria can retreatment with antibiotics, according to a study published today in eLife.
The results show that fast-growing individuals within bacterial colonies display a significantly higher expression of active ribosomes – particles within the cell that synthesise proteins. This helps the bacteria avoid the accumulation of an important class of antibiotics called macrolides and therefore resist therapies. These findings could be used to inform the development of improved antibiotic compounds that target this survival strategy.
Bacterial infections can cause food poisoning, pneumonia, sepsis and other serious diseases. While they can be treated with antibiotics, the overuse of these drugs in recent years means that bacteria are becoming increasingly resistant to them, posing a significant threat to global health.
For an antibiotic to be effective against infection, it needs to reach its cellular target at a sufficient concentration to inhibit bacterial growth.
“Antibiotic resistance continues to threaten the viability of current treatments. We need to understand how individual bacteria within a colony can prevent antibiotics from entering their cells, so that we can target this mechanism with new therapies,” says Urszula Łapińska, PDRA at the University of Exeter, UK. “Most existing data around drug permeability in bacteria has been attained through measurements that either take an average result from a large population or are derived from a small number of bacteria. This means that little is known about the variability in individual drug accumulation across many single cells in a bacterial colony.”
To address this gap, Łapińska and the team began with the hypothesis that variations in how bacteria respond to drugs could be driven by the varying drug transport rates between individual cells. To test this, the team used a multi-analytical approach, combining microfluidics-microscopy, bacteria that pose a health threat – namely Escherichia coli, Pseudomonas aeruginosa, Burkholderia cenocepacia and Staphylococcus aureus and fluorescent probes derived from antibiotics by Dr Mark Blaskovich at the University of Queensland. This approach allowed the team to examine the interactions between commonplace antibiotics and many live, individual bacteria in real-time, during drug dosage. By combining this approach with mathematical modelling techniques developed by Prof Krasimira Tsaneva-Atanasova at the University of Exeter, the team obtained data that they could use to quickly and efficiently identify individual bacteria that are antibiotic resistant.
Their analyses demonstrated that fast-growing individuals within a colony avoid the accumulation of macrolides within their cells – a discovery that contrasts with current thinking that slow cell growth is the major contributor to survival to antibiotics without genetic variation. This avoidance is enabled by a significantly higher amount of ribosomes before drug treatment, compared to the individuals’ slow-growing counterparts. Ribosomes enable essential cellular processes, including efflux – a system that pumps toxic substances, such as antimicrobial compounds, out of the cell.
Using this new knowledge, the researchers then showed that chemically manipulating the outer membrane of the bacterial cells allows to eradicate fast-growing variants that exhibit low macrolide accumulation, therefore aiding our fight against antibiotic resistance.
“This work reveals a hitherto unrecognised survival strategy in some members of bacterial colonies ,” concludes Dr Stefano Pagliara, Senior Lecturer in Microfluidics at the University of Exeter, UK. “These insights will directly benefit microbiologists and clinicians who are working on the development of more effective antibiotic therapies. In the longer term, we hope that using our novel approach in clinical settings will help inform the design of improved drugs and help us in the fight against antibiotic resistance.”
About eLife
eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. From the research we publish, to the tools we build, to the people we work with, we’ve earned a reputation for quality, integrity and the flexibility to bring about real change. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
